The short version of Mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
== January 26, 1982 (Tuesday) == Prime Minister Mauno Koivisto was elected President of Finland by the 301-member Electoral College, receiving 167 votes. He was sworn in the next day to succeed longtime president Urho Kekkonen. Koivistor had obtained 43% of the popular vote in voting on January 17 and January 18 The government of Israel's Prime Minister Menachem Begin survived a vote of no confidecnce by a margin of 55 to 52 regarding compensation to be paid to Israeli citizens who had settled in the Sinai Peninsula, scheduled to be returned to Egypt after 15 years. U.S. President Ronald Reagan delivered his first State of the Union speech since taking office and proposed "New Federalism", the transfer of administration and control of funding for social programs from the U.S. Department of Health and Human Services to the individual state governments. In India, the popular Tamil language film Vaazhvey Maayam (Life is an Illusion), directed by R. Krishnamoorthy, opened at theaters and would run for almost seven months. The romantic drama starred Kamal Haasan, Sridevi and Sripriya. The "Palace on Wheels", a luxury tourist train operated by Indian Railways and the Rajasthan Tourism Development Corporation, began operations. Born: Mamta Kharab, Indian field hockey player and captain of the women's national team; in Givana, Sonipat district, Haryana state Died: Jean Outland Chrysler, 60, American philanthropist and art collector whose donation of works formed the Chrysler Museum of Art; in Norfolk, Virginia
==== Information laundering ==== Generative AI has been noted for its use by state-sponsored propaganda campaigns in information laundering. According to a 2025 report by Graphika, generative AI is used to launder articles from Chinese state media such as China Global Television Network through various social media sites in an attempt to disguise the articles' origin.
== History == Many theories of the origin of the Weimaraner have been advanced, but there are few documented historical facts; silver-grey dogs are shown in paintings by Antoon van Dyck in the seventeenth century and by Jean-Baptiste Oudry in the eighteenth. The breed is believed to have originated in the area of the city of Weimar (then in Saxe-Weimar-Eisenach, now in the state of Thuringia) – the city from which its name derives. It is sometimes claimed that the dogs were kept at the court of Karl August, Grand Duke of Saxe-Weimar-Eisenach, in the early nineteenth century. From 1879 the dogs were considered to be a blue variant of the German Short-haired Pointer, and were eligible for registration in the stud-book of the Kurzhaar Klub. They first appeared at a dog show in 1880, when fourteen examples were presented in Berlin. These were of three differing types, from three different kennels: the traditional Thüringer Hund; the Weißenfelser Hund, which was rather more elegant; and the Sanderslebener, which was intermediate between the two. The Weimaraner was recognised as a distinct breed in 1891. A breed standard was drawn up in 1896, and in 1897 a breed association was established in Erfurt with the name Verein zur Reinzucht des silbergrauen Weimaraner-Vorstehhund; this was soon changed to Verein zur Züchtung des Weimaraner Vorstehhundes. In the early years of the twentieth century – the time of the Great War – the Weimaraner came close to extinction; it was reconstituted from the few surviving examples of the breed.
In January 2018, a class action lawsuit was filed against LifeVantage in Connecticut alleging that the company and its chief executive officer Darren Jensen, chief sales officer Justin Rose, and chief marketing officer Ryan Goodwin were operating an illegal pyramid scheme in violation of the RICO Act, federal securities laws, and the Connecticut Unfair Trade Practices Act.
Sources: en.wikipedia.org
May 21, 1992: Decree concerning the responsibilities of the Secretary of State for Women's Rights and Consumer Affairs. July 22, 1992: Law reforming the provisions of the Penal Code relating to the repression of crimes and offenses against persons. November 2, 1992: Law concerning abuse of authority in sexual matters in work relationships and amending the Labour Code and the Code of Criminal Procedure. January 8, 1992: Law amending the Civil Code concerning civil status, family, and children's rights, and establishing the family affairs judge. January 27, 1993: Law concerning various social measures, notably establishing the offense of obstructing abortion and decriminalizing self-induced abortion. April 8, 1993: Decree concerning the responsibilities of the Minister of State, Minister of Social Affairs, Health, and the City. July 22, 1993: Law reforming nationality law. August 2, 1993: Law concerning the control of immigration and the conditions of entry, reception, and residence of foreigners in France. April 21, 1994: Discussion on the possibility of quotas and potential gender parity in the exercise of responsibilities, particularly political ones. July 15, 1994: Law concerning the family. July 29, 1994: Law concerning respect for the human body. July 29, 1994: Law concerning the donation and use of elements and products of the human body, medically assisted procreation, and prenatal diagnosis. June 1, 1995: Decree concerning the responsibilities of the Minister for Intergenerational Solidarity. October 18, 1995: Creation of the Observatory for Gender Parity.
Unattached/marginal/free gingiva The free gingiva is the unattached coronal portion of the gingival tissue that surrounds the tooth in a collar-like fashion. In a healthy periodontium, it measures approximately 1 mm in width and is not directly bound to the underlying alveolar bone.
Stagnation pressure is the pressure a fluid exerts when it is forced to stop moving. Consequently, although a fluid moving at higher speed will have a lower static pressure, it may have a higher stagnation pressure when forced to a standstill. Static pressure and stagnation pressure are related by:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.